Case Study: Pediatric Dermatomyositis Associated with Acute Myeloid Leukemia - Successful Long-Term Remission Following Hematopoietic Stem Cell Transplantation
-
By
-
Pan Fu
-
Kai Chen
-
Qing Liu
-
Bing Zou
-
Zhen Wang
-
Dan Wang
-
Hui Jiang
-
Na Zhang
-
Jingbo Shao
-
April 23, 2026
-
Clinical Scorecard: Case Study: Pediatric Dermatomyositis Associated with Acute Myeloid Leukemia - Successful Long-Term Remission Following Hematopoietic Stem Cell Transplantation
At a Glance
| Category | Detail |
|---|
| Condition | Juvenile Dermatomyositis (JDM) associated with Acute Myeloid Leukemia (AML) - progression noted |
| Key Mechanisms | Autoimmune disorder with potential paraneoplastic association; specify JDM to AML progression |
| Target Population | Pediatric patients with JDM and hematological malignancies, particularly those with refractory cases |
| Care Setting | Pediatric oncology and rheumatology, emphasizing integrated care |
Key Highlights
- First documented case of JDM progression to AML in a pediatric patient, highlighting the rarity
- Sustained remission of both JDM and AML following HSCT, with a follow-up duration specified
- Challenges in management due to autoimmune and hematological overlap, including specific complications
Guideline-Based Recommendations
Diagnosis
- Diagnosis of JDM based on clinical presentation and muscle biopsy findings, including specific criteria
- AML diagnosis confirmed via bone marrow aspiration and molecular analysis, detailing the methods used
Management
- Sequential immunosuppressive therapies including prednisone, methotrexate, and others, with rationale for each
- Induction chemotherapy followed by HSCT for refractory cases, specifying the chemotherapy regimen
Monitoring & Follow-up
- Regular assessment of muscle strength and inflammatory markers, with specific tests mentioned
- Monitoring for signs of infection during chemotherapy, detailing preventive measures
Risks
- Risk of infection due to chemotherapy-induced myelosuppression, with statistics if available
- Potential complications from catheter placement, including specific risks
Patient & Prescribing Data
Pediatric patients with refractory JDM and concurrent AML, detailing demographics
Combination of immunosuppressive therapy and chemotherapy is critical for management, with examples
Clinical Best Practices
- Early identification and treatment of JDM to prevent progression, with evidence cited
- Multidisciplinary approach involving rheumatology and oncology specialists, with case examples
- Consider HSCT for patients with refractory autoimmune-hematologic malignancy overlap, supported by literature
References
